These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 2753281)

  • 1. [Influence of pH in the adsorption capacity of bile salts and lysolecithins in vitro by antacids containing clay and/or aluminum].
    Vatier J; Olivier JF; Vitre MT; Papazian A
    Gastroenterol Clin Biol; 1989 May; 13(5):445-51. PubMed ID: 2753281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adsorption of bile acids by sucralfate, antacids, and cholestyramine in vitro.
    Ståhlberg M; Jalovaara P; Laitinen S; Mokka R; Hentilä R; Järvensivu P; Kairaluoma M
    Clin Ther; 1987; 9(6):615-21. PubMed ID: 3440273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ability of antacids and cholestyramine to bind bile acids: effect of pH.
    Mangnall YF; Smythe A; Johnson AG
    Scand J Gastroenterol; 1986 Sep; 21(7):789-94. PubMed ID: 3775246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antacids and bile salts.
    Kivilaakso E
    Scand J Gastroenterol Suppl; 1982; 75():16-9. PubMed ID: 6755652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of antacids on the binding of bile salts.
    Cousar GD; Gadacz TR
    Arch Surg; 1984 Sep; 119(9):1018-20. PubMed ID: 6477113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding properties in vitro of antacids for conjugated bile acids.
    Clain JE; Malagelada JR; Chadwick VS; Hofmann AF
    Gastroenterology; 1977 Sep; 73(3):556-9. PubMed ID: 19335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of cimetidine and ranitidine with aluminum-containing antacids and a clay-containing gastric-protective drug in an "artificial stomach-duodenum" model.
    Vatier J; Harman A; Castela N; Droy-Lefaix MT; Farinotti R
    J Pharm Sci; 1994 Jul; 83(7):962-6. PubMed ID: 7965675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Binding of bile salts and lysolecithin by various antacids in biological media].
    Guthauser UJ; Häcki WH
    Schweiz Med Wochenschr; 1987 Feb; 117(9):322-7. PubMed ID: 3563454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of pH and amount of antacids on bile acid binding in a quasi-natural reflux milieu].
    Kurtz W; Güldütuna S; Leuschner U
    Z Gastroenterol; 1991 May; 29(5):237-41. PubMed ID: 1950032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the in vitro interaction of D-penicillamine with antacids.
    Allgayer H; Paumgartner G
    Arzneimittelforschung; 1983; 33(3):417-8. PubMed ID: 6683517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro adsorption of bile salts and aspirin to sucralfate.
    Graham DY; Sackman JW; Giesing DH; Runser DJ
    Dig Dis Sci; 1984 May; 29(5):402-6. PubMed ID: 6546915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of bile acids, antacids, and cholestyramine on transmural electrical potential difference in man.
    Caspary WF; Kausch H
    Acta Hepatogastroenterol (Stuttg); 1978 Oct; 25(5):369-75. PubMed ID: 31754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of bile acids in the development of peptic lesions. Studies on the bile acid-binding capacity of a new kind of antacid].
    Kurtz W
    Fortschr Med; 1991 Oct; 109(29):592-4. PubMed ID: 1783351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adsorption of bile acids and lysolecithin by antacids.
    Begemann F; Schumpelick V; Bandomer G
    Scand J Gastroenterol Suppl; 1981; 67():191-3. PubMed ID: 6941407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bile salt binding by maalox, sucralfate, and meciadanol: in vitro and clinical comparisons.
    Lipsett P; Gadacz TR
    J Surg Res; 1989 Nov; 47(5):403-6. PubMed ID: 2682004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of antacid characteristics of drugs containing a combination of aluminium and magnesium salts using the "artificial stomach" model.
    Vatier J; Vitre MT; Lionnet F; Poitevin C; Mignon M
    Arzneimittelforschung; 1990 Jan; 40(1):42-8. PubMed ID: 2339999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neutralizing capacity, pepsin inactivation and binding to bile acids and lysolecithin of the antacid magaldrate (author's transl)].
    Baur C; Becker A; Linder R; Schwan T
    Arzneimittelforschung; 1981; 31(3):504-7. PubMed ID: 6784737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Binding of antacids to bile acids (author's transl)].
    Caspary WF; Graf S
    Dtsch Med Wochenschr; 1978 May; 103(19):825-7. PubMed ID: 648358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemico-physical property and bile acid binding capacity of several antacids].
    Salvioli G; Tambara E; Gaetti E; Lugli R
    Minerva Dietol Gastroenterol; 1989; 35(2):79-83. PubMed ID: 2548124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antacid action of the aluminum cation: comparison of the in vitro effect of hydroxide and phosphate in open and closed systems].
    Vatier J; Lionnet F; Vitre MT
    Gastroenterol Clin Biol; 1987 Nov; 11(11):758-63. PubMed ID: 3428519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.